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Pyrene-based heparin sensors in competitive aqueous media ʹ 
the role of self-assembled multivalency (SAMul) 
Ching W. Chan
a
 and David K. Smith
a,
* 
Amine-functionalised pyrene derivatives are reported and their 
ability to detect heparin via a fluorescent response determined ʹ 
different responses are observed dependent on whether self-
assembled multivalent binding between sensor and analyte takes 
place, and ratiometric heparin sensors which can detect this 
surgically-relevant polyanion in competitive media are reported. 
Heparin is the most charge-dense naturally-occurring 
polyanion in biological systems.
1
  Clinically, it is used as an anti-
coagulant during cardiopulmonary surgery and to treat 
emergency deep venous thrombosis (DVT).
2
 The quantification 
of heparin levels in blood is typically achieved via an activated 
clotting time assay,
3
 which has the drawback of being 
relatively slow, and unable to be performed on a patient in 
situ.
4
 Therefore, the development of heparin sensors which 
operate in biologically-relevant conditions is of considerable 
interest.
5
  In recent years, a variety of heparin sensors have 
been reported  ? for example using electrochemical6 or 
colorimetric
7
 methods.  Fluorescent heparin sensors are of 
particular interest,
8
 however, some of those reported have 
limitations such as poor selectivity, short emission 
wavelengths, single-wavelength detection (necessitating 
external calibration), or low-affinity in competitive media.  It is 
ǁŽƌƚŚŶŽƚŝŶŐƚŚĂƚĂŶƵŵďĞƌŽĨƐĞŶƐŽƌƐǁŚŝĐŚƌĞƉŽƌƚďŝŶĚŝŶŐ ?ŝŶ
ƐĞƌƵŵ ? ĂĐƚƵĂůůǇ ĂĐŚŝĞǀĞ ƚŚŝƐ ďǇ ĂĚĚŝŶŐ Ă ƐŵĂůů ĂŵŽƵŶƚ ŽĨ
heparinised serum to the sensor in buffer  ? in the assay itself, 
levels of serum are relatively low (<10%).  The development of 
robust, ratiometric dual-wavelength heparin sensors which 
operate in highly-competitive media remains a desirable goal. 
 In sensor technology, pyrene is a useful fluorophore for 
ratiometric sensors, as it can form an excimer when excited-
state and ground-state molecules are brought into close 
proximity.
9
 Self-assembled pyrene derivatives have been used 
to intervene in biological processes.
10
  Several pyrene 
derivatives have been reported as heparin sensors.
11
 In some 
cases, low affinities necessitated the use of co-solvents during 
heparin-binding assays, although sophisticated peptide-
functionalised pyrene derivatives have been reported to 
achieve ultra-sensitive heparin detection.
11e 
 Multivalency, in which multiple interactions form between 
binder and target, is an effective way of achieving high-affinity 
binding to nanoscale surfaces, such as that of polyanionic 
heparin,
5
 in competitive media.
12
 Self-assembled multivalency 
(SAMul), in which non-covalent self-assembly is used to 
organise multiple ligands, which as a result show high-affinity 
binding to a target, has emerged as a strategy of interest.
13
  
We have employed this approach to develop heparin 
binders.
14
  In this new research, we reasoned that pyrene 
could act as a both a fluorescent unit to detect heparin 
ratiometrically and also provide the driving force for self-
assembly.  This could offer a two-in-one approach to high-
affinity binding and ratiometric sensing.   
Figure 1.  Structures of Py-1 and Py-2  ? fluorescent heparin sensors. 
 We targeted relatively simple pyrene-derived sensors  ? 
synthetic simplicity is a desirable feature for sensors with 
potential clinical applications.  Two pyrene derivatives were 
synthesised (Py-1 and Py-2, Fig. 1), each functionalised with 
the same amine ligand (di-3-aminopropylmethylamine, 
DAPMA), in order to explore the effects of ligand organisation 
on self-assembly, multivalent heparin binding and sensing.  
The synthesis of Py-1 was trivially achieved by coupling pyrene 
carboxylic acid to mono-Boc-protected DAPMA, followed by 
deprotection with HCl.  The synthesis of Py-2 employed click 
chemistry to couple a divalent DAPMA ligand, developed by us 
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14
 to the pyrene.  After optimisation, these 
syntheses worked in good yields (for full details, see ESI). 
 The ability of Py-1 and Py-2 to self-assemble in buffered 
water was examined by fluorescence spectroscopy.  The 
pyrene unit was excited at 363 nm and emission intensity 
recorded at 495 nm (Fig. 2).  The concentration at which this 
excimer emission band significantly increased in intensity was 
taken to represent the critical aggregation concentration 
(CAC).  Under these micromolar conditions, Py-1 did not self-
assemble, with the fluorescence intensity remaining low, and 
increasingly linearly across the whole concentration range.  
However, Py-2 showed a discontinuous increase in 
fluorescence intensity on increasing concentration, and the 
CAC was estimated as 21 ± 4 ʅD in PBS buffer. We suggest 
that the more flexible structure of Py-2 and the different 
balance of hydrophilic/hydrophobic groups compared to Py-1, 
give it greater propensity to self-assemble.  
Figure 2 Fluorescence intensity associated with the excimer band of Py-2 at 495 
nm (excitation at 363 nm) as recorded for increasing amounts of Py-2 in PBS 
Buffer.  The discontinuity is taken as an approximation to the critical aggregation 
concentration. 
 The self-assembled nanostructures formed by Py-2 were 
then visualised using transmission electron microscopy (TEM).  
The system appeared to form relatively polydisperse spherical 
assemblies with approximate diameters ranging from ca. 10 to 
40 nm (Fig. 3)  ? given the (much smaller) molecular size (2-3 
nm), these could be vesicular objects or clusters of micellar 
assemblies which aggregate on drying.   
Figure 3. TEM image of Py-2 dried from aqueous solution (1 mg/mL). Scale bar = 
100 nm.  
 Dynamic light scattering (DLS), which investigates self-
assembled objects in solution (rather than deposited on a 
surface as in TEM) supported the formation of self-assembled 
nanostructures (12.3 ± 3.7 nm, Fig. S1) for Py-2.  As expected, 
the zeta potential of these self-assembled nanostructures was 
positive (+27.9 ± 1.4 mV) as a result of protonation of the 
DAPMA ligands at physiological pH.  As such, these self-
assembled nanostructures might be expected to show high 
affinity towards polyanionic heparin.  It should be noted that 
DLS is recorded at relatively high (1 mg/ml) concentration (2.2 
mM for Py-1 and 1.1 mM for Py-2).  Under these conditions, 
Py-1 also self-assembled (Fig. S2).  Aggregation at elevated 
concentrations was also supported by TEM (Fig. S3), in which 
samples were dried from millimolar aqueous solutions.  This 
demonstrates some potential of Py-1 to assemble, but not at 
the concentrations used for heparin binding (60 PM) as 
described in the next section.   
Figure 4.  Fluorescence intensities extracted at 383 nm and 495 nm for the 
titration of heparin into Py-1 (top) and Py-2 (bottom).  Images are included 
(under UV lamp irradiation) of samples in the absence (left) and presence (right) 
of heparin. 
 We then monitored the binding of both Py-1 and Py-2 to 
heparin.  In particular, we initially wanted to determine if 
there was any difference in terms of sensing ability induced by 
the ability of Py-2 to self-assemble in aqueous solution.  We 
titrated heparin (in 10 mM Tris HCl buffer with 150mM NaCl) 
into a buffered solution of the binder (Fig. 4 and Figs. S4 and 
S7).  Compound Py-1, which does not self-assemble, had a 
larger emission peak at 383 nm and a smaller ratio of I495/I383, 
reflecting its monomeric nature, while Py-2 had a much larger 
I495/I383 ratio, indicative of the fact it is self-assembled.  On 
titrating Py-1 with heparin, the emission at 383 nm decreased 
in intensity, however the excimer emission band at 495 nm 
was largely unaffected.  In stark contrast, for Py-2, the 
fluorescence emission intensity at 383 nm decreased while the 
excimer emission band at 495 nm increased very significantly. 
This increased emission band at 495 nm is attributed to the 
formation of pyrene excimers being further induced by 
heparin ďŝŶĚŝŶŐ ? ůĞĂƌůǇ ? ƚŚĞ ƐƚƌŽŶŐ  ?ƐǁŝƚĐŚ-ŽŶ ? excimer 
emission can also be seen using the naked eye when the 
sample is under UV irradiation (Fig. 4 inset photograph), as the 
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fluorescence changes colour (and intensity) to be somewhat 
ŵŽƌĞ  ?ŐƌĞĞŶ ? ? dŚĞƌĞ ǁĂƐ ŶŽ ƐƵĐŚ  ?ŶĂŬĞĚ ĞǇĞ ? ĐŚĂŶŐĞŝŶ ƚŚĞ
emission of Py-1. 
 These observations suggest that the large increase in 
excimer emission intensity is associated with the self-assembly 
of Py-2, and importantly, the reinforcement of this self-
assembly event as a result of multivalent binding to 
polyanionic heparin.  We have noted previously that self-
assembly can induce multivalency, and also, conversely, that 
multivalent binding can induce/reinforce self-assembly.
14,15
  
Clearly, the fluorescence sensing mechanisms of Py-1 and Py-2 
are significantly different under these conditions, with Py-2 
exhibiting what we define here for the first times as a self-
assembled multivalent ( ?SAMul ?) sensing mechanism.  
Figure 5, The changes of the fluorescence intensity ratio of Py-G1 and Py-G2 
(log(I495/I383)) plotted against increasing heparin concentration in buffer. 
 By treating the data extracted at 383 nm and 495 nm, 
these compounds report on heparin concentrations in buffer 
solution through a ratiometric approach. The emission 
intensity ratio, I495/I383, increases as the concentration of 
heparin increases.  To obtain a linear plot, log(I495/I383) was 
plotted against heparin concentration (Fig. 5).  Comparing the 
ratiometric response for Py-1 and Py-2, it is evident that Py-2 
shows a much larger response.  This is a result of the switching 
on of excimer emission by SAMul binding in Py-2 leading to a 
much larger increase in I495 and hence giving more than one 
order of magnitude difference in I495/I383. Compound Py-2 
shows a linear response to heparin under these assay 
conditions from 1-10 PM  ? the clinically relevant range.  
Although Py-1 shows a measurable response in its I383 band 
(Fig. 4)  ? this is relatively insignificant in the ratiometric 
approach (Fig. 5).  Compound Py-1 is less effective as a sensor 
under these conditions  ? although the response is somewhat 
linear, the dynamic range is very small.  As such, under these 
conditions, the SAMul effect of Py-2 makes it a much more 
effective and useful heparin sensor and the difference 
between SAMul and non-SAMul sensing is clear.  We note that 
heparin is a polydisperse target with highly variable binding 
sites along the polymer chain  ? as such, we do not attempt to 
determine binding constants in this case. 
 We then monitored the ability of these sensors to detect 
heparin in 12.5% serum  ? this provides a serum-level typical of 
medicinal assays in which heparinised serum is added to a 
sample of sensor in buffer (Figs. S5 and S8).  In this more 
competitive medium, the response of the sensor to heparin is 
somewhat more linear, and does not saturate in the same way 
 ? this would be reflective of the weaker binding expected in 
the more competitive medium.  However, both sensors did 
show broadly linear responses across the clinically important 
range of 1-10 PM heparin (Fig. 6).  Comparing Py-1 and Py-2 it 
is evident that in both cases, the ratio of peaks I495/I383 
increases with increasing amounts of heparin, suggesting an 
increasing excimer/monomer ratio.  For Py-2, this ratio is 
significantly more in favour of the excimer than for Py-1, but in 
neither case does the excimer fully dominate, as it did for Py-2 
in buffer.  As such, we suggest that self-assembled 
multivalency (SAMul) is somewhat disrupted by 12.5% serum.  
We propose this is due to components in serum, such as 
albumins, which can interact with the hydrophobic domains of 
the SAMul nanostructures and limit self-assembly.
16
  
Figure 6, The changes of the fluorescence intensity ratio of Py-G1 and Py-G2 
(log(I495/I383)) plotted against increasing heparin concentration in 12.5% serum.. 
 The binding data can be explained by a model in which 
these sensors bind to heparin in serum, hence bringing pyrene 
units into close proximity and encouraging excimer emission, 
reflecting a less-ordered self-assembly process induced on the 
heparin backbone, rather than full self-assembled multivalency 
prior to, and reinforced by, heparin binding.  Interestingly, Py-
1 operates quite well in 12.5% serum  ? demonstrating that 
very simple sensors can actually be quite efficient in clinically 
relevant conditions  ? perhaps Py-1, in which the pyrene is 
closer to the cationic ligands, is more readily brought into close 
proximity to other pyrenes once heparin binding occurs.   
 We then went on and tested both sensors in 100% serum.  
However, neither sensor showed a significant response under 
these highly competitive conditions (Figs. S6 and S9).  In an 
attempt to detect a response, we therefore increased the 
concentration of the sensor ca. 10-fold.  Under these 
conditions, we were able to detect the heparin  ? albeit at 
concentrations above clinically-relevant levels (Figs. S10 and 
S11).  The mechanisms of response were similar to those seen 
in 12.5% serum, although in this case, the excimer band of Py-
2 became the dominant feature in the fluorescence spectrum 
 ? suggesting that even under highly competitive conditions, at 
these elevated concentrations the SAMul sensing mechanism 
can still operate to some extent  ? i.e. the elevated 
concentration means the self-assembled nanostructures are 
better able to resist the disruptive effect of serum 
components.  It was clear from this assay that Py-2 could still 
act as an effective heparin sensor under these conditions (Fig. 
S12).  The study also indicates, once again, the surprising 
ability of even very simple Py-1 to respond.  Overall, it is 
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remarkable that a simple dication (Py-1) and tetracation (Py-2) 
can respond to heparin in such highly competitive media.  We 
propose that the amphiphilic ligand design, and ability of 
pyrene to assemble after binding to heparin, play significant 
roles in assisting heparin sensing. 
 In summary, this paper demonstrates that two different 
pyrene derivatives can act as effective heparin sensors in 
competitive media using a ratiometric fluorescence sensing 
approach.  In buffered aqueous solution, the assembly Py-2 
into pre-formed self-assembled multivalent (SAMul) 
nanostructures provides it with a significant (order of 
magnitude) advantage in terms of the dynamic range of 
sensory response and its ability to give a naked eye response 
(in comparison to non-assembling Py-1). This is the first 
example of which we are aware, in which SAMul-enhanced 
sensing has been reported and as such, we consider it a new 
mechanism for analyte detection.  In the presence of serum, 
both ligands can still detect heparin ratiometrically  ? however, 
in this case, the SAMul sensing mechanism of Py-2 is switched 
off (although at elevated concentrations, evidence for this 
mechanism can still be seen, even in 100% serum).  Instead, 
sensing appears to occur due to a degree of assembly taking 
place once these cations have bound to heparin.  We note that 
if SAMul-enhanced sensing could be more effectively 
maintained in serum (as it is in buffer), then this would be a 
very effective way of achieving heparin sensing, and would 
extend the detection of heparin in 100% serum down to lower 
concentrations.  We suggest that future work in the field of 
SAMul sensors should aim to (i) target different analytes with 
high affinity and (ii) achieve enhanced serum stability.  In this 
way, the unique SAMul sensory response can, as well as 
working in highly competitive buffer (where it may be of very 
significant use in its present form), also be applied in true 
highly competitive biological conditions or to samples present 
only at very low concentrations. 
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Graphical Abstract 
Simple functionalised pyrene derivatives can achieve ratiometric sensing of heparin with the precise sensing 
mechanism depending on whether the sensor self-assembles into a multivalent ligand display. 
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